The unspecified funding will support significant expansion of manufacturing capacity at Ecovia Bio’s Livonia facility to meet growing global demand for its AzuraBase and AzuraGel families of gamma polyglutamic acid and specialty biopolymer products across cosmetics, personal care, agriculture, and hygiene applications.
“Microplastics have emerged as one of the most pressing environmental and public health challenges of our time,” Ecovia Bio said in a press statement. Ecovia Bio’s biodegradable γ-PGA technology represents a transformative solution, enabling manufacturers to replace these persistent synthetic polymers with a biobased, fully biodegradable alternative that delivers equivalent or superior performance without environmental or health consequences.”